BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu S, Luttrell LM, Premont RT, Rockey DC. β-Arrestin2 is a critical component of the GPCR-eNOS signalosome. Proc Natl Acad Sci U S A 2020;117:11483-92. [PMID: 32404425 DOI: 10.1073/pnas.1922608117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Moens U. Role of Signaling Pathways in the Viral Life Cycle 2.0. Int J Mol Sci 2022;23:7857. [PMID: 35887205 DOI: 10.3390/ijms23147857] [Reference Citation Analysis]
2 Sun YY, Wu DQ, Yin NN, Yang L, Chen X, Li HD, Li XF, Huang C, Meng XM, Wang H, Li J. Arrb2 causes hepatic lipid metabolism disorder via AMPK pathway based on metabolomics in alcoholic fatty liver. Clin Sci (Lond) 2021;135:1213-32. [PMID: 33871024 DOI: 10.1042/CS20201363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Schierwagen R, Dietrich P, Klein S, Uschner FE, Ortiz C, Tyc O, Torres S, Hellerbrand C, Sauerbruch T, Trebicka J. β-Arrestin2 is increased in liver fibrosis in humans and rodents. Proc Natl Acad Sci U S A 2020;117:27082-4. [PMID: 33144522 DOI: 10.1073/pnas.2014337117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
5 Cheng H, Guo P, Su T, Jiang C, Zhu Z, Wei W, Zhang L, Wang Q. G protein-coupled receptor kinase type 2 and β-arrestin2: Key players in immune cell functions and inflammation. Cellular Signalling 2022. [DOI: 10.1016/j.cellsig.2022.110337] [Reference Citation Analysis]
6 Berthier A, Johanns M, Zummo FP, Lefebvre P, Staels B. PPARs in liver physiology. Biochim Biophys Acta Mol Basis Dis 2021;1867:166097. [PMID: 33524529 DOI: 10.1016/j.bbadis.2021.166097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Johnstone EKM, Ayoub MA, Hertzman RJ, See HB, Abhayawardana RS, Seeber RM, Pfleger KDG. Novel Pharmacology Following Heteromerization of the Angiotensin II Type 2 Receptor and the Bradykinin Type 2 Receptor. Front Endocrinol (Lausanne) 2022;13:848816. [PMID: 35721749 DOI: 10.3389/fendo.2022.848816] [Reference Citation Analysis]
8 Marrache MK, Rockey DC. Statins for treatment of chronic liver disease. Curr Opin Gastroenterol 2021;37:200-7. [PMID: 33654016 DOI: 10.1097/MOG.0000000000000716] [Reference Citation Analysis]
9 Liu S, Luttrell LM, Premont RT, Rockey DC. Reply to Schierwagen et al.: β-Arrestins in liver disease. Proc Natl Acad Sci U S A 2020;117:27085-6. [PMID: 33144523 DOI: 10.1073/pnas.2014931117] [Reference Citation Analysis]
10 Ma TL, Zhou Y, Zhang CY, Gao ZA, Duan JX. The role and mechanism of β-arrestin2 in signal transduction. Life Sci 2021;275:119364. [PMID: 33741415 DOI: 10.1016/j.lfs.2021.119364] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Taguchi K, Kaneko N, Okudaira K, Matsumoto T, Kobayashi T. GLP-1 modulates insulin-induced relaxation response through β-arrestin2 regulation in diabetic mice aortas. Acta Physiol (Oxf) 2021;231:e13573. [PMID: 33098611 DOI: 10.1111/apha.13573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lee C, Viswanathan G, Choi I, Jassal C, Kohlmann T, Rajagopal S. Beta-Arrestins and Receptor Signaling in the Vascular Endothelium. Biomolecules 2020;11:E9. [PMID: 33374806 DOI: 10.3390/biom11010009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]